Abivax ABVX
NASDAQ ABVX
$91.44 +1.44 (+1.60%)
At close: Nov 11, 2026 · 4:00 PM EST

Abivax (ABVX) EBITDA (2024 - 2026)

Updated

Abivax (ABVX) reported EBITDA of -$97.33 million for Q2 2026, compared with -$52.35 million a year earlier.

Analysis

Abivax (ABVX) EBITDA (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Abivax's EBITDA came in at -$339.85 million; for FY2025, it was -$276.79 million.

  • By year, EBITDA came in at -$186.04 million in FY2024, -$137.02 million in FY2023, -$67.82 million in FY2022 and -$48.64 million in FY2021.
  • The Q2 2026 figure ranks as the lowest quarterly EBITDA since Q4 2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$65.4 million (Q1 2026), -$83.08 million (Q4 2025) and -$94.04 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 8.95 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 8.16 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 7.34 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 5.99 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 4.83 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 4.20 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 7.05 Bn
10 Abivax 7.07 Bn 4.69 Bn - -97.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -97.33 Mn
Mar 31, 2026 -65.40 Mn
Dec 31, 2025 -83.08 Mn
Sep 30, 2025 -94.04 Mn
Jun 30, 2025 -52.35 Mn
Mar 31, 2025 -49.36 Mn
Dec 31, 2024 -184.46 Mn
Sep 30, 2024 -54.85 Mn
Jun 30, 2024 -37.65 Mn
Mar 31, 2024 -48.30 Mn
API Access

Abivax EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=ABVX&period=max&api_key=YOUR_API_KEY